Current advances in the understanding of penile carcinogenesis provide the possibility for new personalized and actionable targeted therapeutic approaches to improve outcomes in men with advanced penile cancer. Targeting the human epidermal growth factor receptor pathway showed promising results in a recent phase II trial of first-line therapy with dacomitinib.
Refers to Necchi, A. et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: results of an open label, single-arm, single-center, phase 2 study. BJU Int. http://dx.doi.org/10.1111/bju.14013 (2017)